ARTICLE | Clinical News
Dexanabinol: Phase I ongoing
May 19, 2014 7:00 AM UTC
e-Therapeutics resumed enrollment in an investigator-led, open-label, dose-escalation, U.S. Phase I trial evaluating 2, 4, 8 and 16 mg/kg ETS2101 on days 1, 8, 15 and 22 of a 28-day cycle in up to 24 ...